A 10-year clinicopathological analysis of ovarian lesions in a tertiary hospital in Southern Nigeria

Aniekan M Abasiattai¹, Chukwuemeka C Nwafor², Ntiense M Utuk¹

- 1. Department of Obstetrics/Gynaecology, College of Health Sciences, University of Uyo.
- 2. Department of Pathology, College of Health Sciences, University of Uyo.

Abstract

Background: Ovarian tumours are the most lethal of all gynaecological cancers and they are usually diagnosed in advanced stages when the `prognosis is very poor.

Objective: To determine the pattern of ovarian lesions, their frequency, presentation, and associated clinical symptoms in Uyo, Nigeria.

Methods: A 10-year retrospective study of all ovarian specimens that were surgically removed and histologically diagnosed.

Results: The patients were between the ages of 5 and 73 years with median age of 34.1 years. Benign tumours occurred most commonly among the 20–39-year age group (31.3%) while malignant tumours were predominant among those aged 50-69 years (10.0%). Surface epithelial tumours (45.4%) were the most common neoplastic tumours while the mature cystic teratoma (33.2%) was the most common tumour overall. Surface epithelial malignancies accounted for 70.6% of all ovarian malignancies and the serous cyst adenocarcinoma (10.2%) was the most common surface epithelial tumour as well as the most common malignant tumour.

Conclusion: There has been an increase in the number of malignant ovarian specimens in our centre. Though surface epithelial tumours were the most common category of ovarian tumours, overall, the mature cystic teratoma was the most common tumour. Serous cyst adenocarcinoma was the most common surface epithelial tumour and the most common malignant tumour. **Keywords:** Ovary tumours; ovarian malignancy; malignant tumours; benign tumours; histopathology Uyo.

DOI: https://dx.doi.org/10.4314/ahs.v23i1.48

Cite as: Abasiattai AM, Nwafor CC, Utuk NM. A 10-year clinicopathological analysis of ovarian lesions in a tertiary hospital in Southern Nigeria. Afri Health Sci. 2023;23(1):459-68. https://dx.doi.org/10.4314/ahs.v23i1.48

Introduction

Lesions of the ovary constitute a significant source of morbidity and mortality particularly in the developing world. They are classified into non neoplastic lesions (inflammatory and functional cysts), and neoplastic lesions which include benign, borderline and malignant ovarian tumours ¹.

The frequency of benign ovarian tumours varies with age and the most common benign ovarian tumours in young and elderly women are the germ cell and surface epithelial tumours². Though the majority of benign ovar-

Corresponding author:

Aniekan M Abasiattai,

Department of Obstetrics/Gynaecology, College of Health Sciences, University of Uyo, Uyo Nigeria

Tel: +2340823174734

Email. animan74@yahoo.com

ian tumours are asymptomatic, they can cause menstrual abnormalities, pressure symptoms like frequency of micturition, dyspareunia, abdominal pain which may be severe when torsion occurs and signs of peritonitis if they rupture ³.

Ovarian tumours represent about 30% of all cancers of the female genital tract and 4% of cancers in women ⁴. They are the most lethal of all gynaecological cancers partly due to their insidious presentation and anatomic location as well as their intrinsic histological and molecular heterogenicity ⁵. In addition, they are the cause of more deaths than every other malignancy affecting females ⁶. Ovarian cancers have been described as silent killers as they are often difficult to detect until they are advanced in stage or size as their symptoms are non-specific, vague and insidious ⁷.

There are an estimated 192,000 cases of ovarian cancer per year worldwide and unfortunately, the majority (75%)



© 2023 Abasiattai AM et al. Licensee African Health Sciences. This is an Open Access article distributed under the terms of the Creative commons Attribution License (https://creativecommons.org/licenses/BY/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

are diagnosed with advanced disease (stages III and IV) when the 5-year survival rate is less than 20% ⁵. There is great variation in the geographic distribution of ovarian cancer with the highest incidence reported to be in North America and Europe especially the Nordic countries and the United Kingdom ⁵. Interestingly, a previous report from this centre ⁸ and indeed other centres in Nigeria ⁹⁻¹¹ reveal that ovarian cancer is the second most common gynaecological cancer in these environments after cancer of the cervix.

Since the establishment of our centre, there has been no known study on ovarian lesions. Hence, this study aims to determine the pattern of ovarian lesions, their frequency, presentation, and associated clinical symptoms in the University of Uyo Teaching Hospital.

Material and Methods

This is a retrospective study of all ovarian specimens (OS) that were surgically removed and histologically diagnosed in the Obstetrics/Gynaecology and Histopathology Departments of University of Uyo Teaching Hospital (UUTH) respectively over a 10 year period (from January 1, 2010 to December 31, 2019). UUTH, a 500-bed hospital is the only tertiary hospital in Akwa Ibom State and also serves as a referral centre for the neighbouring states. The histopathology laboratory in UUTH is the main facility where histopathology services are rendered in Akwa Ibom State and as such render's services to the host hospital and many privately owned and public hospitals. These OS included cystectomies, oophorectomies, incisional biopsies and hysterectomies. Following laparotomies, these OS were immediately fixed in 10% buffered formalin, auto-processed, and paraffin embedded sections were taken and stained with hematoxylin and eosin. Special stains were used when necessary.

Data were extracted from the patients' case files and theatre registers. Other major sources of information were histopathological departmental registers, patient request forms, and duplicate copies of histology reports of all cases. Information extracted included the age of patients, major symptom/s prior to presentation, duration of symptom/s before presentation, laterality of the tumour, clinical diagnosis, maximum diameter and weight of the specimen, type of specimen received and histologic diagnosis. The OS were classified histologically into cystic lesions, inflammatory lesions and neoplastic lesions. The neoplastic lesions were further sub-classified using the World Health Organisation's (WHO) international classification of ovarian tumours (into surface epithelial, germ cells and sex cord stromal tumours) ¹². Data were analysed using predictive analytical software, version 17 (IBM, SPSS Inc., Chicago, IL, USA).

Simple frequencies were determined for categorical variables and the mean was evaluated for continuous data. Ovaries that were part of hysterectomy specimens performed due to non-ovarian lesion indications, like those due to endometrial lesions, myometrial lesions and cervical lesions were excluded. OS from incidental ovarian cystectomies performed during elective caesarean sections (CS) were included. Few reports with ambiguous conclusions were excluded. Also excluded were OS reports with any of the major identification parameters (such as age and histologic diagnosis) missing. Six reports in all were excluded.

Since the aim of our study was to document pathological ovaries seen, those from hysterectomies of non-ovarian indications were excluded because they are almost always normal. In addition, most hysterectomies in our centre are performed for myometrial and endometrial lesions.

Results

A total of 7,028 histologic specimens were received in the department of Histopathology during the 10 years under review, while ovarian tissues (excluding ovaries that were part of hysterectomies performed for other reasons like, cervical, endometrial and myometrial lesions) were 160 accounting for 2.3% of all histopathologic specimens.

Over the years there had been a mild increase in the number of specimens sent for histologic examination. Two peaks (year 2012 and 2019) were observed to have the highest number of ovarian specimens. There had been a marginal increase in the number of malignant ovarian specimens since the year 2014, as shown in table 1. Year 2019 recorded the highest number of malignant ovarian lesions though, that was the year also with the highest number of specimens sent in for examination.

Table 1: Yearly pattern of ovarian specimens in relation to ovarian malignant lesions

Year	Total	All ovarian	Malignant		
	specimens	specimens	ovarian lesion		
2010	530	7	0		
2011	638	9	4		
2012	650	23	2		
2013	782	19	2		
2014	595	11	2		
2015	722	13	5		
2016	685	14	4		
2017	762	17	5		
2018	753	18	4		
2019	911	29	6		
Total	7028	160	34		

Table 2 shows the presenting complaints, duration of symptoms prior to presentation, clinical diagnoses, laterality of the ovarian lesions/mass and procedure performed by the gynaecologist. The earliest a patient presented was within two days of onset of symptoms, while the longest interval before presentation was 15 years (180 months), with a mean duration of 24.2 ±35.15 months. A significant proportion of the patients (22.5%) presented at least more than one year after onset of symptoms. The minimum diameter of ovarian specimens seen was 2cm, while the widest diameter seen was 47cm. The weight of ovarian specimens ranged from 100g to 40000g with a mean weight of 2361g. Right ovary specimens accounted for most (30.6%), while cystectomy (58.8%) was the commonest surgical procedure performed by the gynae-

cologist. Ovarian tumour or ovarian cyst (47.5%) was the most commonly made provisional diagnosis.

diagnoses include each of Others in clinical the following: ectopic pregnancy, intra-abdominal malignancy, Poly cystic ovarian syndrome, ovarian abscess, endometriosis, and uterine sarcoma. Other presenting complaints included: Primary infertility, dysmenorrhea, breathlessness, Irregular menses, bleeding per rectum, leg swelling, constipation, lower urinary tract obstruction, vaginal discharge and each of the following: post-menopausal bleeding, sprouting of pubic hair in a school age child, breast enlargement, easy satiety, acute abdomen, melena stool and found incidentally during a myomectomy.

Table 2: Pre histologic characters of the ovarian specimens

Table 2: Pre histologic characters of the ovarian specimens							
Various Characteristics	Frequency	Percentage (%)					
Clinical Diagnoses							
Ovarian tumor/cyst	76	47.5					
Ovarian torsion	14	8.8					
Ovarian malignancy	14	8.8					
Meigs syndrome	6	3.8					
Others	8	4.8					
Not stated	42	26.3					
Laterality							
Left	34	21.3					
Right	49	30.6					
Bilateral	22	13.8					
Not stated	55	34.3					
Surgical procedure							
Cystectomy	94	58.8					
Oophorectomy	30	18.8					
Hysterectomy	26	16.3					
Incisional biopsy	3	1.7					
Not stated	7	4.4					
Duration of symptoms							
before presentation							
< 3 months	30	18.8					
4-6 months	13	8.1					
7-11 months	7	4.4					
1 year and above	36	22.5					
Not stated	74	46.2					
Presenting complaints							
Lower abdominal pain	75	46.9					
Abdominal swelling	57	35.6					
Abdominal mass	23	14.4					
Weight loss	10	6.3					
Removed during	7	4.4					
elective CS	6	3.8					
Per vagina bleeding	6	3.8					
Amenorrhea	6	3.8					
Vomiting	46	27.6					
Others							
							

All the specimens were from phenotypically and genetically females. The youngest patient was 5 years old and the oldest 73 years old with a mean age of 34.13±13.78. Generally, age groups 20-29 years, closely followed by 30-39 years accounted for more than 66.0% of cases, while benign neoplastic lesions were the commonest histologic

category of specimens seen. For the malignant lesions, age group 50-59 years alone accounted for 32.4% of cases as shown in table 3. Neoplastic ovarian lesions (benign, borderline and malignant lesions) accounted for 67.5% of all diagnoses made histologically with malignant ovarian tumours consisting of 21.2%.

Table 3: Age group distribution of ovarian specimens in relation to major histologic category of lesion

Histologic	< 19	20-29	30-39	40-49	50-59	60-69	70-79	Total	Percentage
category	years	years	years	years	years	years	years		(%)
Benign neoplastic lesions	5	28	22	7	3	5	1	71	44.4
Cystic non neoplastic lesions	1	19	18	1	-	-	-	39	24.4
Malignant neoplastic lesions	4	5	4	4	11	5	1	34	21.2
Inflammatory lesions	3	2	6	-	-	1	-	12	7.5
Borderline malignant lesions	-	-	1	1	1	-	-	3	1.9
Ectopic normal tissue	-	-	1	-	-	-	-	1	0.6
Total	13 (8.1%)	54 (33.8%)	52 (32.5%)	13 (8.1%)	15 (9.4%)	11 (6.9%)	2 (1.2%)	160 (100%)	100%

P = 0.000

Neoplastic ovarian tumours made up 108 (67.5%) of the specimens. Tumours of surface epithelial origin accounted for 45.4%, closely followed by tumours of germ cell origin (40.7%). The most common benign tumours of epithelial origin were the serous cyst adenomas (8.3%), while serous cyst adenocarcinomas were the most common malignant tumour of epithelial origin (10.2%) and

also the most common malignant tumour overall. Mature teratomas (MT) were not only the most predominant germ cell tumour, but were also the most common tumour seen overall accounting for 33.2% of all ovarian tumours. Involvement of both ovaries by the same pathology was observed in a case of serous cyst adenocarcinoma, endometrioid carcinoma and serous cyst adenoma. In 2 situations, bilateral MT was observed (table 4).

Table 4: Histopathologic diagnoses of neoplastic ovarian specimens

Table 4: Histopathologic diagnoses of	•		
Histopathologic diagnoses	Frequency	Percentage	
Benign surface epithelial lesions			
(n=22)	0	0.2	
Serous cyst adenoma	9	8.3	
Mucinous cyst adenoma	8	7.4	
Mucinous cyst adenofibroma	1	0.9	
Serous cyst adenofibroma	3	2.8	
Left M C A and right Brenner's	1	0.9	
tumor			
Borderline surface epithelial (n=3)			
Borderline mucinous cyst	3	2.8	
adenoma			
Malignant surface epithelial lesions			
(n=24)			
Serous cyst adenocarcinoma	11	10.2	
Mucinous cyst adenocarcinoma	9	8.3	
Endometrioid carcinoma	2	1.9	
Transitional cell carcinoma	1	0.9	
Malignant mixed mullerian tumor	1	0.9	
Benign sex cord stromal lesions (n =			
7)	3	2.8	
Fibrothecoma	2	1.9	
Adult granulosa cell tumor	1	0.9	
Fibroma	1	0.9	
Thecoma			
Malignant sex cord stromal tumors			
(n=3)			
Adult type granulosa cell tumor	2	1.9	
Fibrosarcoma	1	0.9	
Benign germ cell tumors (n = 41)			
Mature teratoma	36	33.2	
Struma ovarii	2	1.9	
Left corpus luteum cyst and	3	2.8	
right M T	J	2.0	
Malignant germ cell tumors (n =3)			
Immature teratoma	2	1.9	
Malignant transformation of a M T	1	0.9	
Other benign tumors (n = 1)		0.7	
Leiomyoma	1	0.9	
Leioniyoma	1	0.7	
Metastatic tumors (n = 4)			
Non-Hodgkin's lymphoma	2	1.9	
Krukenberg tumor	2	1.9	
Total	108	100	

M T = Mature teratoma

The age range of patients with malignant ovarian tumours was between 5 years and 71 years with a mean age of 43.59 ± 17.72 . The sizes of malignant ovarian specimens ranged from 2cm to 47cm with a mean diameter of 16.48cm ± 8.27 . The mean weight of malignant ovarian specimens was 4402grams ± 9009.27 . The least number of malignant lesions was seen in age group 70-79 years (2.8%), while the highest was seen in age group 50-59 years (32.4%). The remaining cases were roughly equally

distributed across the other age groups as shown in table 5. Surface epithelial origin malignancies accounted for 70.6% of all ovarian malignancies seen. Germ cell and sex cord stromal malignancies each accounted for 8.8% of malignant ovarian lesions respectively. Involvement of both ovaries by the same malignant pathology was observed in a case of serous cyst adenocarcinoma (in a patient aged 57 years) and endometrioid carcinoma (in a patient aged 15 years).

Table 5: Age group distribution of malignant ovarian tumours

Malignant Age group distribution of malignant ovarian tumours Malignant Age group								
diagnosis	<19	20-29	30-39	40-49	50-59	60-69	70- 79	Total (%)
Serous cyst adenocarcinoma	-	1	-	1	6	2	1	11(32.4)
Mucinous cyst adenocarcinoma	1	1	1	2	2	2	-	9 (26.5)
Endometrioid carcinoma	1	1	-	-	-	-	-	2 (5.9)
Krukenberg tumor	-	-	-	-	2	-	-	2 (5.9)
Immature teratoma	2	-	-	-	-	-	-	2 (5.9)
Malignant adult type granulosa tumor	-	-	1	-	1	-	-	2 (5.9)
Non-Hodgkins lymphoma	-	2	-	-	-	-	-	2 (5.9)
Transitional cell carcinoma	-	-	1	-	-	-	-	1 (2.9)
Malignant mixed mullerian tumor	-	-	1	-	-	-	-	1 (2.9)
Malignant transformation of MT	-	-	-	-	-	1	-	1 (2.9)
Fibrosarcoma	-	-	-	1	-	-	-	1 (2.9)
Total	4 (11.8)	5 (14.7)	4 (11.8)	4 (11.8)	11 (32.4)	5 (14.7)	1 (2.8)	34 (100)

P = 0.133

Cystic lesions of the ovary were the most common non neoplastic lesions seen in this study (75%). Corpus lute-

um cyst, closely followed by follicular cyst and simple cyst each accounted for 23.1%, 21.2% and 21.2% respectively as shown in table 6.

Table 6: Non neoplastic histologic diagnoses

Non neoplastic lesions	Frequency	Percentage
Cystic ovarian lesions (n = 39)		
Corpus luteum cyst	12	23.1
Follicular cyst	11	21.2
Simple cyst	11	21.2
Corpus haemorrhagicum	3	5.8
Luteoma of pregnancy	1	1.9
Polycystic ovarian	1	1.9
syndrome		
Inflammatory lesions ($n = 12$)		
Abscess / oophoritis	7	13.5
Ovarian torsion	5	9.5
Ectopic normal tissue $(n = 1)$		
Endometriosis	1	1.9
Total	52	100

Discussion

This study reveals the pattern of ovarian lesions in our centre. The mean age of our patients was 34.1 years with benign tumours occurring most commonly among the 20-39 years age group, while malignant tumours were found predominantly among those aged between 50-69 years. These findings are consistent with those of other researchers 13,14, who have also documented these age groups to be the most commonly affected by benign and malignant neoplastic tumours in their series. Benign neoplastic lesions were in the majority as they accounted for 65.7% of the specimens. However, the proportions of benign and malignant tumours in our study (65.7% and 34.3%) were at variance with those from other centres where the percentages of benign and malignant tumours were 84.9% and 13.4% ¹, 84.7% and 15.3% ², 78.3% and 18.4% ⁴, and 83.8% and 14.4% ¹⁴ relatively. Available reports from Caucasian and Western countries also indicate that 75.0%-80.0% of ovarian tumours are benign, while malignant tumours account for the remaining 20.0%-25.0% 4. Hence, when compared with what obtains in the Western world and several centres in Asia, the proportion of ovarian tumours that are malignant in our environment is much higher.

Overall surface epithelial tumours were the most common ovarian tumours and were very closely followed by tumours of germ cell origin. This is in accordance with reports from several other researchers ^{1,13-16}. However, not only were the mature teratomas which are benign germ

cell tumours the most common ovarian lesions in our study, they were also more common than the total sum of all other benign tumours. Studies conducted in Nigeria and indeed other parts of Sub-Saharan Africa have also revealed the mature cystic teratomas to be the most common ovarian tumours in their various populations ^{2,17-20}. This finding is completely at variance with what obtains in the North America, Europe and Asia where mostly serous cystadenomas or mucinous cyst adenomas, which are both benign surface epithelial tumours, are much more common ^{1,4,13-16}.

Due to the retrospective nature of our study, the reason for the high preponderance of the dermoid cysts in African populations could not be discerned. However, this predisposition is likely to be due to racial factors as shown in a South African study19 where there was a predominance of germ cell tumours in blacks (52.0%) as opposed to Indians (19.0%), with benign cystic teratoma accounting for most of the cases.

Malignant tumours made up a significant proportion of all the specimens as they constituted a third of all lesions. Malignant surface epithelial tumours accounted for about 70% of all ovarian malignancies. The proportion of malignant surface epithelial tumours in our study is much higher than those recorded by several other authors ^{1,2} ^{13,14}. Furthermore, serous cystadenocarcinoma which was the most common malignant tumour in our study was also the most common surface epithelial lesion. Though,

the benign serous cystadenoma is documented to be the predominant surface epithelial tumour and occurs much more commonly than its malignant form in most other series ^{1,2,13,14,18,21}, the converse was the case in ours as its malignant form was much more common.

While literature shows that the majority of mucinous tumours are benign ^{13,16}, with 20.0% being borderline and 5.0% invasive ¹³, in our series, the mucinous cysadenocarcinoma constituted 26.5% of all malignant ovarian tumours, was the second most common malignant ovarian tumour, occurred more commonly than its benign form, and occurred at the same frequency with the benign serous cystadenoma. This seems to suggest that in contrast to what is in available literature, the malignant mucinous cyst adenocarcinoma is not uncommon in our environment.

It is also worrisome that in our study, not only have ovarian malignancies increased in number over the last year, but they were also found in adolescents, half of whom had the very virulent malignant surface epithelial tumours. In a study conducted by Ahmed et al in Dhaka, Pakistan ¹, all cases of ovarian malignancy that occurred in patients under 20 years of age were germ cell in origin. Malignant germ cell tumours have a better prognosis when compared to malignant surface epithelial tumours and they are often cured with conservative surgery and chemotherapy with preservation of fertility ²².

Functional cysts (corpus luteum, follicular and simple cysts) were the most common non-neoplastic cysts in our series. This is similar to the findings of Amin et al in Lagos, Nigeria ¹⁷ and Neelgund et al in Pondicicherry, India ²¹ but different from those of Naik et al in Sattur, India ¹⁴ were chocolate cysts where much more common. Functional or physiological cysts are large versions of cysts that form in the ovary during the normal menstrual cycle. They are asymptomatic, resolve spontaneously and often do not require any treatment ²¹.

The common symptoms associated with ovarian lesions were lower abdominal pain, abdominal swelling and an abdominal mass. This is similar to what obtains in other reports ¹⁴. The symptoms of ovarian tumours are non-specific and vague and there are no distinguishing symptoms that differentiate benign from malignant ovarian tumours ²³. Indeed, malignant ovarian tumours are

frequently asymptomatic until they are advanced in stage ¹⁴. Hence, it is imperative clinicians maintain a high index of suspicion in-order to detect ovarian malignancy early; ensure prompt treatment with an ultimate increase in survival from the disease and a decrease in treatment related morbidity.

This study was retrospective in nature and was conducted in a tertiary health facility, thus it may not be representative of what obtains in the community.

In conclusion, there has been an increase in the number of malignant ovarian specimens in our centre. Neoplastic ovarian tumours were the commonest lesions; however, the percentage of malignant tumours was high which is at variance with findings from studies in Asia and the Western world. Though surface epithelial tumours were the most common category of ovarian tumours, overall, the mature cystic teratoma was the most common tumour. Not only was the serous cyst adenocarcinoma the most common surface epithelial tumour, it was also the most common malignant tumour in the study. Thus, practicing clinicians must maintain a high index of suspicion in order to detect ovarian malignancy early and offer prompt treatment.

Conflict of interest

None

References

- 1. Ahmed M, Afroze N, Sabiha M. Morphologic pattern of ovarian tumours: experience in a tertiary level hospital. *J Bangladesh Coll Phys Surg* 2018; 36:3-10 PubMed .
- 2. Forae GD, Aligbe JU. Ovarian tumours among Nigeria females: A private practice experience in Benin City, Nigeria. *Adv Biomed Research* 2015: 61.
- 3. Al zahidy ZA. Causes and management of ovarian cysts. *The Egyptian J Hosp Med* 2018; 70: 1818-1822.
- 4. Agarwal D, Kaur S, Agarwal R, Gathwal M. Histopathological analysis of neoplastic lesions in the ovary: A 5-year retrospective study at tertiary health care centre. *Int J Contemp Med Research* 2018; 5: E14-E17.
- 5. Halcomb KM, Caputo TA, Knapp RC. Diagnosis of ovarian cancer. *Progress in Obst Gynae* 2008; 18: 329-342.
- 6. Hanoch J, McIndoe A. Improving the prognosis in ovarian cancer. *Progress in Obst Gynae* 2005; 16: 357-370.
- 7. Mankar DV, Jain GK. Histopathological profile of ovarian tumours: A twelve-year institutional experience. *Muller J Med Sci Res* 2015; 6: 107-111.

- 8. Bassey EA, Ekpo MD, Abasiattai AM. Female genital malignancies in Uyo, South-south Nigeria, *The Nig Post-grad Med J* 2007; 14:134-136.
- 9. Sanni WO, Ocheke AN, Oyebode T, Jonah M, Nyango DD, Silas OA et al. Pattern of gynaecological malignancies in Jos. *Trop J Obstet Gynaecol* 2013; 30: 97-102.
- 10. Airede IR, Malami SA. A five-year review of female genital tract malignancies in Sokoto, North Eastern Nigeria. *Mary Slessor J Med* 2005; 5: 51-56 PubMed.
- 11. Umanah IN, Ugiagbe EE, Olu-Eddo AN. Female genital tract malignancies in a Niger-Delta region of Nigeria. *Ibom Med J* 2013; 6: 23-28.
- 12. Ehdaivand S. WHO classification of ovarian neoplasms. Pathology Outlines.com. https://www.pathologyoutlines.com/topic/ovarytumorwhoclassif.html. Accessed April 4th, 2020.
- 13. Hashmi AA, Hussain ZF, Bhagwani AR, Edhi MM, Faridi N, Hussain SD et al. Clinicopathologic features of ovarian neoplasm with emphasis on borderline tumours: an institutional perspective. *BMC Res Notes* 2016; 9: 205
- 14. Nail S, Kumar SKS, Girija B. Clinicopathological analysis of ovarian tumours: a 10 year retrospective study: *Int J Reprod Contracept Obstet Gynaecol* 2018; 7: 3216-3221 PubMed.
- 15. Nishal AJ, Naik KS, Modi J. Analysis of spectrum of ovarian tumours: a study of 55 cases. *Int J Res Med Sci* 2015; 3: 2714-2717 PubMed .
- 16. Mondal SK, Banyopdhyay R, Nag DR, Roychowdhury S, Mondal PK, Sinha SK. Histologic pattern, bilat-

- erality and clinical evaluation of 975 ovarian neoplasms: A 10-year study in a tertiary hospital of eastern India. *J Cancer Res Therapeutics* 2011; 7: 433-437.
- 17. Amin SM, Olah F, Babandi RM, Liman MI, Abubakar SJ. Histopathological analysis and clinical correlation of ovarian lesions in a tertiary hospital in Nigeria: A 10-year review. *Annals Trop Path* 2018; 25-28.
- 18. Akakpo PK, Derkyi-Kwarteng L, Gyasi RK, Quayson SE, Naporo S, Anim JT. A pathological and clinical study of 706 primary tumours of the ovary in the largest teaching hospital in Ghana. *BMC Women's health* 2017; 17: 34.
- 19. Moorman PG, Palmieri RT, Akushevich L, Berchcuk A, Schildkraut JM. Ovarian cancer risk factors in African-American and white women. *Am J Epidemiol* 2009; 170: 598-606.
- 20. Onyiaorah IV, Anunobi CC, Banjo AA, Fatima AA, Nwankwo KC. Histopathological patterns of ovarian tumours seen in Lagos University Teaching Hospital: a ten-year retrospective study. *Nig Q J Hosp Med* 2011; 21: 114-118 PubMed.
- 21. Neelgund S, Hiremath P. A retrospective study of ovarian cysts. *Int J Reprod Contracept Obstet Gynaecol* 2016; 5: 1960-1973.
- 22. Mona A, Dobbs S (eds). Diseases of the ovary. Gynaecology by Ten Teachers 2011.19th ed Hodder Arnold. London: 110-119.
- 23. Garg N, Amandl AS, Annigeri C. Study of histomorphological spectrum of ovarian tumours. *Int J Med Health Res* 2017; 3: 12-20 PubMed .